How are RGNX long call max profit and max loss calculated?

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the RGNX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 81.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$87.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a RGNX long call?

The breakeven for the RGNX long call priced on this page is roughly $6.88 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RGNX market-implied 1-standard-deviation expected move is approximately 23.42%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current RGNX implied volatility affect this long call?

RGNX ATM IV is at 81.70% with IV rank near 8.38%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

RGNX Long Call Strategy

RGNX (REGENXBIO Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX (REGENXBIO Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $518.2M, a beta of 1.12 versus the broader market, a 52-week range of 7.35-16.19, average daily share volume of 812K, a public-listing history dating back to 2015, approximately 353 full-time employees. These structural characteristics shape how RGNX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.12 places RGNX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long call on RGNX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current RGNX snapshot

As of May 15, 2026, spot at $5.75, ATM IV 81.70%, IV rank 8.38%, expected move 23.42%. The long call on RGNX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this long call structure on RGNX specifically: RGNX IV at 81.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a RGNX long call, with a market-implied 1-standard-deviation move of approximately 23.42% (roughly $1.35 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RGNX expiries trade a higher absolute premium for lower per-day decay. Position sizing on RGNX should anchor to the underlying notional of $5.75 per share and to the trader's directional view on RGNX stock.

RGNX long call setup

The RGNX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RGNX near $5.75, the first option leg uses a $6.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RGNX chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RGNX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$6.00	$0.88

RGNX long call risk and reward

Net Premium / Debit: -$87.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$87.50
Breakeven(s): $6.88
Risk / Reward Ratio: Unbounded

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

RGNX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on RGNX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.8%	-$87.50
$1.28	-77.7%	-$87.50
$2.55	-55.6%	-$87.50
$3.82	-33.6%	-$87.50
$5.09	-11.5%	-$87.50
$6.36	+10.6%	-$51.37
$7.63	+32.7%	+$75.65
$8.90	+54.8%	+$202.68
$10.17	+76.9%	+$329.70
$11.44	+99.0%	+$456.73

When traders use long call on RGNX

Long calls on RGNX express a bullish thesis with defined risk; traders use them ahead of RGNX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

RGNX thesis for this long call

The market-implied 1-standard-deviation range for RGNX extends from approximately $4.40 on the downside to $7.10 on the upside. A RGNX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current RGNX IV rank near 8.38% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RGNX at 81.70%. As a Healthcare name, RGNX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RGNX-specific events.

RGNX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RGNX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RGNX alongside the broader basket even when RGNX-specific fundamentals are unchanged. Long-premium structures like a long call on RGNX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RGNX chain quotes before placing a trade.

Frequently asked questions

What is a long call on RGNX?: A long call on RGNX is the long call strategy applied to RGNX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With RGNX stock trading near $5.75, the strikes shown on this page are snapped to the nearest listed RGNX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are RGNX long call max profit and max loss calculated?: Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the RGNX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 81.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$87.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RGNX long call?: The breakeven for the RGNX long call priced on this page is roughly $6.88 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RGNX market-implied 1-standard-deviation expected move is approximately 23.42%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on RGNX?: Long calls on RGNX express a bullish thesis with defined risk; traders use them ahead of RGNX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current RGNX implied volatility affect this long call?: RGNX ATM IV is at 81.70% with IV rank near 8.38%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.